Clinical Trial Scheme of Huangqi Guizhi Wuwu Decoction

  • STATUS
    Recruiting
  • participants needed
    360
  • sponsor
    Jiangsu Famous Medical Technology Co., Ltd.
Send
Updated on 16 February 2024
See if I qualify
blood transfusion
neutrophil count
oxaliplatin
capecitabine
bone marrow procedure
adjuvant chemotherapy
immunostimulants
colorectal cancer

Summary

To evaluate the efficacy and safety of Huangqi Guizhi Wuwu decoction in preventing oxaliplatin induced peripheral neurotoxicity.

Description

The purpose of this study is to evaluate whether the preventive effect of Huangqi Guizhi Wuwu decoction on oxaliplatin induced peripheral neurotoxicity is better than that of simulator, and to provide evidence-based medicine basis for the clinical promotion of single medicine granule. This trial purpose is to evaluate the efficacy and safety of Huangqi Guizhi Wuwu decoction in preventing oxaliplatin induced peripheral neurotoxicity. This trial design type is a randomized, controlled, double-blind, multicenter clinical study was conducted.

Details
Condition Oncology
Age 18years - 75years
Treatment Huangqi Guizhi Wuwu decoction
Clinical Study IdentifierNCT04261920
SponsorJiangsu Famous Medical Technology Co., Ltd.
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

b'Patients with colorectal cancer diagnosed by histopathological examination; patients'
b'after radical resection of colorectal cancer confirmed by histopathological examination,'
b'taged as high-risk II stage (according to CSCO guidelines for diagnosis and treatment of'
b'colorectal cancer) or III stage, IV stage (metastatic lesions have been radical resection);'
b'Patients who are suitable for receiving oxaliplatin plus capecitabine regimen as'
b'adjuvant chemotherapy for 6 months, the cumulative dose of oxaliplatin are expected to'
b'exceed 520mg/m2 at least; 3. Aged from 18 to 75 years old, males or females; 4. ECOG score'
b'ranges from 0 to 1 5. Seven days before treatment, the functions of major organs (heart,'
b'liver, kidney, bone marrow) meet the following criteria:'
b'Standard of blood routine examination (without blood transfusion within 14 days) i.'
b'Hemoglobin (HB) \\u226590g/L\\uff1b ii. Absolute Neutrophil Count(ANC) \\u22651.5\\xd7109/L\\uff1b. iii. Platelet'
b'(PLT) \\u226580\\xd7109/L.'
b'Biochemical examination should meet the following standards:'
b'Total bilirubin(TBIL) \\u22641.5 times upper normal limit(ULN);'
b'Alanine aminotransferase(ALT) and Aspartate aminotransferase(AST) \\u22642.5 times'
b'ULN\\uff1b'
b'\\u2462Serum creatinine \\uff08Cr\\uff09\\u22641.5 times ULN or Creatinine clearance(CCr) \\u226560ml/min;'
b'Expected survival time\\u226512 months; 7. For subjects who have used other'
b'chemotherapeutic drugs in the past, they need to go through a clearance'
b'period of at least 4 weeks before entering this trial.'
b'The patient who will sign the informed consent form'

Exclusion Criteria

b'Patients with original nervous system diseases, including peripheral neuropathy and'
b'central neuropathy;'
b'Those who are allergic to oxaliplatin or the ingredients of this traditional Chinese'
b'medicine;'
b'Clinical symptoms of patients with severe damp-heat syndrome of colorectal cancer'
b'include: dry mouth, bitter taste in the mouth, sticky sensation in mouth, yellow'
b'urine, dry stool, red tongue with yellow ,thick and greasy fur;'
b'Patients with neurological disease caused by electrolyte disorders or diabetes;'
b'Patients with symptoms of nerve compression caused by various causes;'
b'At the same time, patients who receive other neuroprotective therapy, including nerve'
b'growth factor, vitamin B and calcium-magnesium mixture;'
b'Patients who were treated with oxaliplatin for chemotherapy before;'
b'Patients who need radiotherapy within half a year after operation;'
b'Pregnant or lactation period women;'
b'Patients with cognitive impairment or psychosis;'
b'Other patients the investigator considers unsuitable for inclusion.'
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

blood transfusion
neutrophil count
oxaliplatin
capecitabine
bone marrow procedure
adjuvant chemotherapy
immunostimulants
colorectal cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.